GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Piotroski F-Score

Endologix (Endologix) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Endologix Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Endologix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Endologix's Piotroski F-Score or its related term are showing as below:


Endologix Piotroski F-Score Historical Data

The historical data trend for Endologix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Piotroski F-Score Chart

Endologix Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 3.00 1.00 3.00

Endologix Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 5.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun20) TTM:Last Year (Jun19) TTM:
Net Income was -7.765 + -7.83 + -18.116 + -26.093 = $-59.8 Mil.
Cash Flow from Operations was -4.013 + -5.107 + -9.322 + -22 = $-40.4 Mil.
Revenue was 35.775 + 35.751 + 28.51 + 24.841 = $124.9 Mil.
Gross Profit was 23.074 + 21.829 + 15.132 + 14.153 = $74.2 Mil.
Average Total Assets from the begining of this year (Jun19)
to the end of this year (Jun20) was
(324.291 + 317.517 + 307.164 + 300.353 + 271.415) / 5 = $304.148 Mil.
Total Assets at the begining of this year (Jun19) was $324.3 Mil.
Long-Term Debt & Capital Lease Obligation was $11.1 Mil.
Total Current Assets was $61.4 Mil.
Total Current Liabilities was $229.6 Mil.
Net Income was -10.116 + -25.955 + -22.028 + -27.134 = $-85.2 Mil.

Revenue was 34.756 + 34.693 + 35.606 + 36.238 = $141.3 Mil.
Gross Profit was 22.627 + 11.366 + 23.199 + 22.984 = $80.2 Mil.
Average Total Assets from the begining of last year (Jun18)
to the end of last year (Jun19) was
(333.738 + 326.331 + 293.07 + 289.493 + 324.291) / 5 = $313.3846 Mil.
Total Assets at the begining of last year (Jun18) was $333.7 Mil.
Long-Term Debt & Capital Lease Obligation was $176.8 Mil.
Total Current Assets was $107.4 Mil.
Total Current Liabilities was $42.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Endologix's current Net Income (TTM) was -59.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Endologix's current Cash Flow from Operations (TTM) was -40.4. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun19)
=-59.804/324.291
=-0.18441462

ROA (Last Year)=Net Income/Total Assets (Jun18)
=-85.233/333.738
=-0.25538896

Endologix's return on assets of this year was -0.18441462. Endologix's return on assets of last year was -0.25538896. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Endologix's current Net Income (TTM) was -59.8. Endologix's current Cash Flow from Operations (TTM) was -40.4. ==> -40.4 > -59.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=11.127/304.148
=0.03658416

Gearing (Last Year: Jun19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun18 to Jun19
=176.836/313.3846
=0.56427789

Endologix's gearing of this year was 0.03658416. Endologix's gearing of last year was 0.56427789. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun20)=Total Current Assets/Total Current Liabilities
=61.407/229.598
=0.26745442

Current Ratio (Last Year: Jun19)=Total Current Assets/Total Current Liabilities
=107.418/42.531
=2.52564012

Endologix's current ratio of this year was 0.26745442. Endologix's current ratio of last year was 2.52564012. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Endologix's number of shares in issue this year was 20.717. Endologix's number of shares in issue last year was 18.142. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=74.188/124.877
=0.59408858

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=80.176/141.293
=0.56744495

Endologix's gross margin of this year was 0.59408858. Endologix's gross margin of last year was 0.56744495. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun19)
=124.877/324.291
=0.38507698

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun18)
=141.293/333.738
=0.42336503

Endologix's asset turnover of this year was 0.38507698. Endologix's asset turnover of last year was 0.42336503. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Endologix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Endologix  (OTCPK:ELGXQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Endologix Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Endologix's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Endologix (Endologix) Business Description

Traded in Other Exchanges
N/A
Address
2 Musick, Irvine, CA, USA, 92618
Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.
Executives
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko director, officer: CEO and Director C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Matthew Thompson officer: Chief Medical Officer 2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady officer: Controller and Corp Secretary 2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto officer: Interim CFO 2 MUSICK IRVINE CA 92618
Jeff Fecho officer: Chief Quality Officer ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob officer: Chief Financial Officer 2 MUSICK IRVINE CA 92618
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John Zehren officer: Chief Commercial Officer 2 MUSICK IRVINE CA 92618
Jeremy B. Hayden officer: General Counsel 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F director 2 MUSICK IRVINE CA 92618